| 23.9675 -0.643 (-2.61%) | 12-05 09:44 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 33.28 | 1-year : | 38.88 |
| Resists | First : | 28.5 | Second : | 33.28 |
| Pivot price | 23.77 |
|||
| Supports | First : | 22.31 | Second : | 18.5 |
| MAs | MA(5) : | 24.3 |
MA(20) : | 22.83 |
| MA(100) : | 18.36 |
MA(250) : | 0 | |
| MACD | MACD : | 1.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 63 |
D(3) : | 61.1 |
| RSI | RSI(14): 57 |
|||
| 52-week | High : | 28.5 | Low : | 3.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRPO ] has closed below upper band by 41.0%. Bollinger Bands are 45.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 26.03 - 26.17 | 26.17 - 26.28 |
| Low: | 23.53 - 23.68 | 23.68 - 23.8 |
| Close: | 24.36 - 24.62 | 24.62 - 24.83 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Thu, 04 Dec 2025
Precipio (PRPO) details limited cloud data access; reports no impact to operations, patients or finances - Stock Titan
Sat, 22 Nov 2025
How Precipio Inc. (PRPO) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Fri, 21 Nov 2025
Precipio announces executive option grants tied to stock performance - MSN
Wed, 19 Nov 2025
Precipio Stock Up Following Solid Q3 Earnings and Improved Cash Flow - TradingView
Wed, 19 Nov 2025
Precipio, Inc. (NASDAQ:PRPO) Stock Rockets 28% But Many Are Still Ignoring The Company - simplywall.st
Mon, 17 Nov 2025
Earnings call transcript: Precipio Q3 2025 sees strong growth and positive EBITDA - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 19.2 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.88 |
| Profit Margin | -5.5 % |
| Operating Margin | -0.9 % |
| Return on Assets (ttm) | -6.9 % |
| Return on Equity (ttm) | -9.8 % |
| Qtrly Rev. Growth | 29.8 % |
| Gross Profit (p.s.) | 5.84 |
| Sales Per Share | 13.02 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -30.14 |
| PEG Ratio | 0 |
| Price to Book value | 3.09 |
| Price to Sales | 1.87 |
| Price to Cash Flow | 48.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|